| Literature DB >> 34188314 |
Samira A Almalki1, Tahani M Bawazeer2, Basim Asghar2, Arwa Alharbi2, Meshari M Aljohani3, Mohamed E Khalifa1, Nashwa El-Metwaly2,4.
Abstract
Two thiazole-basedEntities:
Keywords: COVID-19 drugs; DFT; In-silico; Pharmacophore; Thiazol complexes
Year: 2021 PMID: 34188314 PMCID: PMC8222988 DOI: 10.1016/j.molstruc.2021.130961
Source DB: PubMed Journal: J Mol Struct ISSN: 0022-2860 Impact factor: 3.196
Scheme 1Synthesis steps for thiazole-based ligand (HL).
Fig. 1ESR spectrum of Cu(II)-HL complex.
Fig. 2Mass spectrum of Co(II)-HL complex.
Scheme 2The proposed structures of the complexes.
Characteristic IR- bands for thiazole-based ligand and its complexes.
| Comp. | υ(OH) | υ(NH) | υ(C | υ(CH | υ(C | δ(NH) δ(OH) | υas(OAc) υas(OAc) | ρr(H2O) | ρw(H2O) | υ(M-O) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1)HL (keto/enol form) | 3480 | 3214 | 1681 | 1716 1112 | 1570 | 1534 1379 | — | — | — | — |
| 2)[Co(OAc)(HL)(H2O)2]OAc.2H2O | B. C. 3526 | 1621 | 1651 1032 | 1588 | 1528 | 1528;1334 | 860 | 615 | 552 | |
| 3)[Cu(Cl)2(HL)(H2O)]. 3H2O | 3518 | 3186 | 1632 | 1650 1099 | 1595 | 1543 | — | 887 | 607 | 506 |
B.C., broad centered; the repetition of assignment value due to overlapping between near vibrations.
Fig. 3Frontier orbitals of the keto(A)-enol (B) form of the ligand and its Co(II)-HL (C) and Cu(II)-HL (D) complexes.
Magnetic moments, electronic transitions and ligand field parameters.
| Compound | μeff. (B.M.) | Intraligand and CT transitions | d-d transitions; Assignments (cm1) | 10Dq(cm−1); β, B (cm−1); ʋ1(cm−1) | Geometry | |
|---|---|---|---|---|---|---|
| Co(II)-HL | 4.73 | 40,816; 32,787 25,381 | 15,385;(ʋ2) 19,231 (ʋ3) | 4T1g (F)→ 4A2g(F) 4T1g (F)→ 4T1g(P) | 8285.46; 0.898; 872.15; 7216.0 | Octahedral |
| Cu(II)-HL | 1.70 | 32,258; 28,169 25,773 | 22,472; 17,544 | 2Eg → 2T2g | —– | Octahedral |
CT; Charge Transfer
Fig. 4Iso-surface with array plots of the keto(A)–enol (B) form of the ligand and its Co(II)-HL (C) and Cu(II)-HL (D) complexes.
Fig. 5Pharmacophore query for keto (A, B)–enol (C, D) forms of the ligand towards 7bz5 and 6lu7, respectively, as COVID-19 proteins.
Fig. 6Pharmacophore query search for arbidol(A, B), avigan (C, D) and idoxuridine (E, F) towards 7bz5 and 6lu7, respectively, as COVID-19 proteins.
Binding affinity parameters for the docking complexes with COVID-19 proteins.
| The docking complex | Total energy (Kcal/mol) | Electronic energy (Kcal/mol) | Heat of formation (Kcal) | Ionization potential (eV) | Sum of atomic polariazability |
|---|---|---|---|---|---|
| 1)Keto HL-6lu7 | -74756.054 | -422191.62 | -27.1462 | 9.0727 | 35.2939 |
| 2)Keto HL-7bz5 | -74755.414 | -425670.43 | -26.4334 | 9.3037 | 35.2939 |
| 3)Enol HL-6lu7 | -75403.851 | -438473.65 | -45.1254 | 9.1801 | 36.6275 |
| 4)Enol HL-7bz5 | -75399.757 | -443045.96 | -41.0319 | 9.0144 | 36.6275 |
| 5)Arbidol-6lu7 | -84338.835 | -634783.93 | 28.3387 | 8.7870 | 54.4966 |
| 6)Arbidol-7bz5 | -84337.656 | -613853.68 | 29.5221 | 8.5604 | 54.4966 |
| 7)Avigan-6lu7 | -52500.816 | -224627.42 | -37.7525 | 10.0705 | 19.2198 |
| 8)Avigan-7bz5 | -52500.839 | -224632.92 | -37.7707 | 10.0730 | 19.219 |
| 9)Idoxuridine-6lu7 | -84576.679 | -472147.09 | -169.222 | 9.7855 | 34.7347 |
| 10)Idoxuridine-6bz5 | -84576.796 | -472302.46 | -169.3357 | 9.8431 | 34.7341 |
Scheme 3Pharmacophore analogues drugs obtained from MolPort library for arbidol, avigan & idoxuridine (A,B,C).
Interaction parameters for docking poses for HL ligand and current drugs towards COVID-19 proteins.
| Compounds | Proteins | ligand | Receptor | Interaction | Distance(Å) | E(Kcal/mol) | S(energy score) | Acceptor bonds | Donor bonds |
|---|---|---|---|---|---|---|---|---|---|
| HL(Keto/form) | 6lu7 | —- | —- | —- | —- | —- | -5.828 | 4 | 1 |
| 7bz5 | 5-ring 5-ring | CA TYR 473 (A) N GLN 474 (A) | Pi-H pi-H | 4.25 3.69 | -0.9 -2.2 | -5.0205 | 4 | 1 | |
| HL(Enol/form) | 6lu7 | N6 5-ring | O HIS 164 (A) 5-ring HIS 41 (A) | H-donor pi-pi | 3.09 3.78 | -2.1 -0.0 | -5.9171 | 4 | 2 |
| 7bz5 | —- | —- | —- | —- | —- | -5.1185 | 4 | 2 | |
| Arbidol(Umifenovir) drug | 6lu7 | C17 | 5-ring HIS 41 (A) | H-pi | 3.68 | -0.6 | -7.0452 | 2 | 1 |
| 7bz5 | 6-ring | 5-ring TRP 436 (A) | Pi-pi | 3.96 | -0.0 | 5.6959 | 2 | 1 | |
| Avigan (Favipiravir) drug | 6lu7 | C8 | 5-ring HIS 41 (A) | H-pi | 4.21 | -1.8 | -4.4133 | 3 | 1 |
| 7bz5 | — | —- | —- | —- | —- | -4.2014 | 3 | 1 | |
| Idoxuridine drug | 6lu7 | C3 N6 O14 O16 | O HIS 164 (A) SD MET 49 (A) SG CYS 145 (A) NE2 HIS 163 (A) | H-donor H-donor H-donor H-acceptor | 3.17 3.10 3.27 2.93 | -0.9 -4.5 -1.9 -2.2 | -6.1962 | 5 | 3 |
| 7bz5 | C3 O14 6-ring | OD1 ASN 343 (A) O PHE 342 (A) | H-donor H-donor Pi-pi | 3.37 3.01 3.80 | -1.2 -1.9 -0.0 | -5.1074 | 5 | 3 |